Literature DB >> 12228326

Production and characterization of protective human antibodies against Shiga toxin 1.

Jean Mukherjee1, Kerry Chios, Dianne Fishwild, Deborah Hudson, Susan O'Donnell, Stephen M Rich, Arthur Donohue-Rolfe, Saul Tzipori.   

Abstract

Hemolytic-uremic syndrome (HUS) is a serious complication which is predominantly associated in children with infection by Shiga toxin-producing Escherichia coli (STEC). By using HuMAb-Mouse (Medarex) animals, human monoclonal antibodies (Hu-MAbs) were developed against Shiga toxin 1 (Stx1) for passive immunotherapy of HUS. Ten stable hybridomas comprised of fully human heavy- and light-chain immunoglobulin elements and secreting Stx1-specific Hu-MAbs (seven immunoglobulin M(kappa)() [IgM(kappa)] elements [one specific for the A subunit and six specific for the B subunit] and three IgG1(kappa) elements specific for subunit B) were isolated. Two IgM(kappa) Hu-MAbs (2D9 and 15G9) and three IgG1(kappa) Hu-MAbs (5A4, 10F4, and 15G2), all specific for subunit B, demonstrated marked neutralization of Stx1 in vitro and significant prolongation of survival in a murine model of Stx1 toxicosis.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12228326      PMCID： PMC128343          DOI： 10.1128/IAI.70.10.5896-5899.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  24 in total

Review 1.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome.

Authors:  P M Griffin; R V Tauxe
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

2.  Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin.

Authors:  M S Islam; W H Stimson
Journal:  J Clin Lab Immunol       Date:  1990-09

3.  Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide.

Authors:  H Shimizu; R A Field; S W Homans; A Donohue-Rolfe
Journal:  Biochemistry       Date:  1998-08-04       Impact factor: 3.162

4.  Haemolytic anaemia after childhood Escherichia coli O 157 .H7 infection: are females at increased risk?

Authors:  P C Rowe; W Walop; H Lior; A M Mackenzie
Journal:  Epidemiol Infect       Date:  1991-06       Impact factor: 2.451

5.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.

Authors:  A Donohue-Rolfe; I Kondova; J Mukherjee; K Chios; D Hutto; S Tzipori
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

7.  Isolation of an Escherichia coli O157:H7 strain producing Shiga toxin 1 but not Shiga toxin 2 from a patient with hemolytic uremic syndrome in Korea.

Authors:  Y B Kim; J Okuda; C Matsumoto; T Morigaki; N Asai; H Watanabe; M Nishibuchi
Journal:  FEMS Microbiol Lett       Date:  1998-09-01       Impact factor: 2.742

8.  Animal toxicity of Shigella dysenteriae cytotoxin: evidence that the neurotoxic, enterotoxic, and cytotoxic activities are due to one toxin.

Authors:  K Eiklid; S Olsnes
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

9.  High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

Authors:  D M Fishwild; S L O'Donnell; T Bengoechea; D V Hudson; F Harding; S L Bernhard; D Jones; R M Kay; K M Higgins; S R Schramm; N Lonberg
Journal:  Nat Biotechnol       Date:  1996-07       Impact factor: 54.908

10.  Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.

Authors:  A Donohue-Rolfe; G T Keusch; C Edson; D Thorley-Lawson; M Jacewicz
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307
View more
  29 in total

1.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection.

Authors:  David Montero; Paz Orellana; Daniela Gutiérrez; Daniela Araya; Juan Carlos Salazar; Valeria Prado; Angel Oñate; Felipe Del Canto; Roberto Vidal
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide.

Authors:  Michael J Smith; Humberto M Carvalho; Angela R Melton-Celsa; Alison D O'Brien
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

4.  Monoclonal antibody 11E10, which neutralizes shiga toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin.

Authors:  Michael J Smith; Angela R Melton-Celsa; James F Sinclair; Humberto M Carvalho; Cory M Robinson; Alison D O'Brien
Journal:  Infect Immun       Date:  2009-05-11       Impact factor: 3.441

5.  In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins.

Authors:  Pavel I Kitov; George L Mulvey; Thomas P Griener; Tomasz Lipinski; Dmitry Solomon; Eugenia Paszkiewicz; Jared M Jacobson; Joanna M Sadowska; Missao Suzuki; Ken-Ichi Yamamura; Glen D Armstrong; David R Bundle
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

Review 6.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

Review 7.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2.

Authors:  Donna E Akiyoshi; Abhineet S Sheoran; Curtis M Rich; L Richard; Susan Chapman-Bonofiglio; Saul Tzipori
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

9.  Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.

Authors:  Greice Krautz-Peterson; Susan Chapman-Bonofiglio; Karen Boisvert; Hanping Feng; Ira M Herman; Saul Tzipori; Abhineet S Sheoran
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

10.  In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.

Authors:  Kwang-il Jeong; Susan Chapman-Bonofiglio; Pradeep Singh; Jongo Lee; Saul Tzipori; Abhineet S Sheoran
Journal:  BMC Immunol       Date:  2010-03-24       Impact factor: 3.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.